PEG-rhG-CSF in Secondary Prevention of Nab-Paclitaxel Combined With S-1 in Advanced Pancreatic Cancer

Inclusion Criteria:

* Age ≥ 18 years, ≤70 years;
* Patients with Advanced Pancreatic Cancer diagnosed by histopathology，the expected survival time is more than 3 months;
* Neutropenia of ≥2 degree occurred with the nab-paclitaxel + S-1 regimen in the previous cycle.
* KPS score≥70;
* The peripheral blood routine of the patients was normal: ANC ≥ 2.0x10\^9/L, platelet count ≥ 90x10\^9/L, HB ≥ 80g/L before enrollment, and there was no bleeding tendency;
* Patients volunteered to participate in the trial, signed a written informed consent, willing to be followed up.

Exclusion Criteria:

* There are uncontrollable infections at the moment or systemic antibiotic treatment within 72 h of chemotherapy；
* Any abnormal bone marrow hyperplasia and other abnormal hematopoietic function；
* Patients who had received bone marrow or hematopoietic stem cell transplantation within 3 months；
* Patients with other malignancies that have not been cured or with brain metastases；
* Total bilirubin(TBIL), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \>2.5 ULN, or \>5 ULN if there is liver metastasis;
* Serum creatinine (Cr) exceeded the upper limit of normal value；
* Allergic to this product or other biological products derived from genetically engineered escherichia coli；
* Suffering from a mental or nervous system disorder, without self-awareness or coordination；
* Patients expected to have a short survival or have difficulty tolerating chemotherapy；
* Pregnant or lactating female patients；
* Patients using other drugs of the same category or in clinical trials of other drugs；
* Not suitable for participation at investigators' discretion.